METFORMIN IN OBESE ADOLESCENTS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目前，肥胖症在美国年轻人中流行。因此，与肥胖相关的健康问题，如高血压、高胆固醇水平和糖尿病，在这一人群中也有所增加。尽管缺乏科学数据支持二甲双胍的使用，但许多青少年已经并正在接受二甲双胍治疗肥胖。这项试验将检验这样一种假设，即在肥胖青少年中，与接受安慰剂治疗和相同生活方式干预的受试者相比，使用缓释二甲双胍(GLucphage XR)治疗，再加上生活方式干预，将导致肥胖减少。将对大约135名潜在受试者进行筛查，以便随机选择76名年龄在13-18岁之间的肥胖青少年。肥胖将通过测量每个受试者的身体质量指数(BMI)来评估。BMI提供了一个基于体重和身高的指导方针，以确定一个人的体重是否合适。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, there is an epidemic of obesity among American youth. As a result, health problems related to obesity, such as high blood pressure, elevated cholesterol levels and diabetes, have increased among this population as well. A number of adolescents have been and are currently being treated for obesity with metformin, despite a lack of scientific data supporting its use. This trial will test the hypothesis that among obese adolescents, treatment with extended-release Metformin (Glucophage XR), coupled with a lifestyle intervention, will result in decreased obesity as compared to subjects who receive treatment with placebo and the same lifestyle intervention. Approximately 135 potential subjects will be screened in order to randomize 76 obese adolescents between the ages of 13-18 yrs old. Obesity will be assessed by measuring each subject's body mass index (BMI). BMI provides a guideline based on weight and height to determine whether an individual is at an appropriate weight.